Access to advanced treatments for eye diseases has taken a significant step forward as European health authorities endorse Vgenfli, a new biosimilar medication intended to address various forms of visual impairment. This approval marks a pivotal moment in the management of conditions that can lead to severe vision loss.
Vgenfli’s Mechanism and Efficacy
Vgenfli, developed by Zakłady Farmaceutyczne Polpharma S.A., contains aflibercept as its active ingredient. Aflibercept operates by acting as a decoy receptor for VEGF (vascular endothelial growth factor), effectively inhibiting angiogenesis—the process of new blood vessel formation that contributes to diseases like wet age-related macular degeneration (AMD) and diabetic macular edema (DME). Clinical trials have demonstrated that Vgenfli matches the efficacy and safety profile of Eylea, the reference product approved in the EU since 2012. This similarity ensures that patients receive a treatment that is both reliable and effective.
Regulatory Process and Approval
On June 19, 2025, the Committee for Medicinal Products for Human Use (CHMP) provisionally endorsed the marketing authorization of Vgenfli. The recommendation paves the way for the European Commission to grant full approval, allowing the medicine to enter the market. Vgenfli will be distributed as a 40 mg/ml injection solution available in pre-filled syringes and vials, administered by qualified physicians experienced in intravitreal injections. Detailed usage guidelines will be published in the summary of product characteristics upon authorization.
- Vgenfli offers a cost-effective alternative to existing treatments for severe eye conditions.
- Healthcare providers gain access to another reliable option for patient care.
- The approval may encourage further development of biosimilar therapies in ophthalmology.
The introduction of Vgenfli into the European market not only broadens the therapeutic options for patients suffering from debilitating eye conditions but also underscores the regulatory body’s commitment to fostering competitive pricing and innovation in pharmaceuticals. By ensuring that biosimilars like Vgenfli meet stringent efficacy and safety standards, the European Medicines Agency reinforces its role in supporting both patient outcomes and the sustainability of healthcare systems across member states. This approval is expected to enhance treatment accessibility and potentially reduce the economic burden associated with chronic eye diseases.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
